uniQure Submits Applications for Huntington's Disease Treatment Approval in US and UK

uniQure N.V. has submitted a Biologics License Application to the FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. Concurrently, a Marketing Authorisation Application was filed with the UK's MHRA for the same treatment. These submissions mark a significant step towards potentially making a new therapy available for patients with Huntington's disease.